Bodisen Biotech Appoints Global Law Firm Reed Smith as Legal Counsel
Tuesday April 5, 9:37 am ET

NEW YORK--(BUSINESS WIRE)--April 5, 2005--Bodisen Biotech, Inc., (stock symbol: BBOI, website: /) announced today that it has appointed Reed Smith (/) as its legal counsel that will advise the company with SEC filings and other corporate matters.

Founded in 1877, Reed Smith has 128 years of history and over 1000 lawyers worldwide. The firm is counsel to 29 of the top 30 U.S. banks; 26 of the Fortune e-50 companies; 9 of the top 10 pharmaceutical companies; and 50 of the world's leading drug and device manufacturers.

Ms. Qiong Wang, CEO of Bodisen, commented, "We are pleased to have Reed Smith working with Bodisen. As we look forward to a year of substantial growth, Reed Smith's proven track record and expertise in mergers & acquisitions give us great confidence that the interests of Bodisen and our shareholders will be protected while we pursue various growth opportunities worldwide. The law firm's strong presence in London and expertise on China may lead to new strategic opportunities for us."

Vinay Ganga, partner at Reed Smith London, commented: "Reed Smith is pleased to represent Bodisen, a Forbes 100 growth company in China. I have recently twice visited Bodisen and its newly completed state of the art manufacturing facility located in China. I was impressed with the growth potential of the company, and the extensive knowledge and dedication of its management. Reed Smith is dedicated to serving the needs of growth companies such as Bodisen."

About Bodisen Biotech, Inc.

Utilizing proprietary technologies, Bodisen sells over 60 packaged products in 3 product categories throughout China: Organic Compound Fertilizer; Organic Liquid Fertilizer; and Pesticides & Insecticides. Bodisen's organic fertilizers can be absorbed by plants within 48 hours while enriching soil conditions without the damaging effects associated with chemical fertilizers.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Bodisen Biotech, Inc.
Investor Relations, 212-566-3503
info@bodisen.com

Source: Bodisen Biotech, Inc.